Month: June 2024

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination (“LCD”) for the Company’s kidneyintelX.dkd testing. The final LCD can be accessed at LCD – KidneyIntelX and KidneyIntelX.dkd Testing (L39726) (cms.gov), and is effective for dates of service on or after August 1, 2024. The established Medicare price for kidneyintelX.dkd is $950 per test. Distinct CPT Codes (Common Procedural Terminology Codes) have been established for kidneyintelX.dkd and is published in CMS’ 2024 Clinical Lab Fee Schedule. The LCD specifies...

Flagship Communities Real Estate Investment Trust Announces June 2024 Cash Distribution

Written by Customer Service on June 14, 2024. Posted in Dividend Reports And Estimates.

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, June 14, 2024 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (the “REIT”) (TSX:MHC.U; MHC.UN) announced today a cash distribution of US$0.0492 per REIT unit for the month of June 2024, representing US$0.59 per REIT unit on an annual basis. Payment will be made on or about July 15, 2024, to unitholders of record as of the close of business on June 28, 2024. Distributions paid to Canadian unitholders (and other non-U.S. unitholders) generally will be subject to U.S. withholding tax. Unitholders should consult their own tax advisors for advice with respect to the tax consequences of receiving a distribution from the REIT in their own circumstances. About Flagship Communities Real Estate Investment Trust Flagship Communities...

Auction result of Treasury Bills – RIKV 24 0821 – RIKV 24 1218

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Series RIKV 24 0821 RIKV 24 1218Settlement Date 06/19/2024 06/19/2024Total Amount Allocated (MM) 25,755 30,561All Bids Awarded At (Price / Simple interest) 98.382 / 9.398 95.440 / 9.451Total Number of Bids Received 14 25Total Amount of All Bids Received (MM) 27,355 39,561Total Number of Successful Bids 12 22Number of Bids Allocated in Full 12 22Lowest Price / Highest Simple Interest Allocated 98.382 / 9.398 95.440 / 9.451Highest Price / Lowest Simple Interest Allocated 98.426 / 9.138 95.602 / 9.100Lowest Price / Highest Simple Interest Allocated in Full 98.382 / 9.398 95.440 / 9.451Weighted Average of Successful Bids (Price/Simple Interest) 98.391 / 9.345 95.481 / 9.362Best Bid (Price / Simple Interest) 98.426 / 9.138 95.602 / 9.100Worst Bid (Price / Simple Interest) 98.280 / 10.001 95.394 / 9.551Weighted...

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

Written by Customer Service on June 14, 2024. Posted in Public Companies.

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AMLTUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AMLTUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical StudyTUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly Diagnosed AML Patients; Clinical Sites Being ActivatedSAN DIEGO and TORONTO, June 14, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies,...

Intellia Therapeutics Names Brian Goff to its Board of Directors

Written by Customer Service on June 14, 2024. Posted in Public Companies.

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. “We are very pleased to welcome Brian to our board of directors. Brian’s extensive global commercialization experience, coupled with his track record of success leading rare disease product launches, will be invaluable to Intellia as we commercialize our first CRISPR-based gene editing therapies for people with life-threatening diseases,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We look forward to leveraging Brian’s first-hand experience to guide us through the exciting evolution from late-stage clinical development to a commercial...

Brixton Metals Appoints Patrick Highsmith to its Board of Directors

Written by Customer Service on June 14, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, June 14, 2024 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to announce the appointment of Mr. Patrick Highsmith as a director and Chair of the Company’s Compensation Committee, effective June 11, 2024. Mr. Highsmith has more than 30 years of international experience including operational, exploration and business development roles with major companies such as Newmont Mining, BHP, Rio Tinto, and Fortescue Metals Group. He also has co-founded, and/or acted as a director or senior executive in several junior companies. His junior company pedigree includes Canadian listed companies such as: Lithium One, Bellhaven Copper & Gold, Pure Energy Minerals, Champion Electric Metals, and FireFox Gold, for whom he is co-founder and chairman...

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP) and support development path forward Additional data from the ongoing Phase 1b trial of DISC-0974 in myelofibrosis (MF) patients continued to demonstrate greater than 60% hematologic response rates, with durable increases in hemoglobin levels and reductions in transfusion burden Positive data from initial single-ascending dose (SAD) cohorts of a Phase 1 trial of DISC-3405 in healthy volunteers demonstrated sustained, meaningful induction of hepcidin and >50% suppression of mean serum ironWATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...

Plato Gold Welcomes Mr. Ernie J. Marcotte to the Board of Directors

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Toronto, ON, June 14, 2024 (GLOBE NEWSWIRE) — Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company“) an exploration company with a portfolio of properties in Northern Ontario and Santa Cruz, Argentina is pleased to welcome Mr. Ernie J. Marcotte as the newest member of our Board of Directors. “On behalf of our Board, I am very pleased to welcome Mr. Ernie Marcotte as a new Director. I look forward to working with Ernie who brings a wealth of experience and expertise in the mining sector. Ernie will be joining our seasoned team of professionals, each with a proven record of success in the mining industry or related business sector,” said Anthony Cohen, President and CEO. “I am pleased to serve as a director for Plato Gold and look forward to...

JOYY Inc. Announces the Results of the Repurchase Right Offer for its 1.375% Convertible Senior Notes due 2026

Written by Customer Service on June 14, 2024. Posted in Public Companies.

SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) — JOYY Inc. (Nasdaq: YY) (“JOYY” or the “Company”), a global technology company, today announced the results of its previously announced repurchase right offer relating to its 1.375% Convertible Senior Notes due 2026 (CUSIP No. 98426T AF3) (the “2026 Notes”). The repurchase right offer expired at 5:00 p.m., New York City time, on Thursday, June 13, 2024. Based on information from Citibank, N.A. as the paying agent for the 2026 Notes, US$405,445,000 aggregate principal amount of the 2026 Notes were validly surrendered and not withdrawn prior to the expiration of the repurchase right offer. The aggregate cash purchase price of these 2026 Notes is US$405,445,000. The Company has accepted all of the surrendered 2026 Notes for repurchase and has forwarded cash in payment of the same to the paying...

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Written by Customer Service on June 14, 2024. Posted in Public Companies.

Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains and objective reduction in skin lesions corresponding with symptomatic improvement WALTHAM, Mass. and BOULDER, Colo., June 14, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis (NonAdvSM). The data are being presented today in a poster presentation at the 2024 European Hematology Association (EHA) Congress taking place in Madrid, Spain. “We...

Month: June 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals